

May 22, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format.

**Title: Myelofibrosis: prognostication and cytoreductive treatment**

**Author:** Margherita Maffioli, Domenica Caramazza, Barbara Mora, Michele Merli, Francesco Passamonti

**Name of Journal:** *World Journal of Hematology*

**ESPS Manuscript NO:** 7072

Manuscript has been improved according to the suggestions of reviewer.

Revision #1

This is a comprehensive and updated review on the prognosis and treatment of idiopathic myelofibrosis. All the parts of the manuscript are well balanced and provide useful information.

1. Only minor changes are suggested 1. Page 4 (top). Given that the concept of complex karyotype can vary among diseases, I suggest including the definition of complex karyotype for myelofibrosis.

**R: in the revised version, the definition has been added.**

2. Page 11 and 12. Given the importance of the data of long-term follow-up of COMFORT-2 trial (2 years and 3 years), I suggest including the 95% confidence intervals corresponding to the HR of 0.58 and 0.48, respectively.

**R: in the revised version, the 95%CI has been added.**

**References and typesetting were corrected**

Thank you again for publishing our manuscript in the *World Journal of Hematology*.

Yours sincerely

Francesco Passamonti, MD

Head, Division of Hematology

University Hospital Fondazione Macchi

Viale Borri 57- 21100 Varese, Italy

Tel/Fax: +39 332 393 648

E-Mail: [francesco.passamonti@ospedale.varese.it](mailto:francesco.passamonti@ospedale.varese.it)